Recent Advancement in Nanomedicine for Treatment of Brain Cancer

Aaditya Banjare, Sanskar Tripathi, Reshma Khatoon, Sandip Prasad Tiwari, Santosh Kumar Prajapti*
Faculty of Pharmacy, Kalinga University, Naya Raipur, Chhattisgarh, 492101, India

Abstract:

Cancer is a term used to describe a collection of diseases characterised by abnormal cell proliferation with the ability to infiltrate or spread to other sections of the body., it began to divide quickly and without a pause. According to the World Health Organization, cancer is the second biggest cause of death worldwide, accounting for an estimated 9.6 million deaths in 2018, with most cancers accounting for around one in every six fatalities. Most cancer deaths occur in low- and middle-income nations, accounting for over 70% of all cancer deaths worldwide. Around one-third of cancer deaths are caused by the five most common behavioural and dietary risks: a high BMI, a lack of fruit and vegetable consumption, a lack of physical activity, the use of tobacco, and the use of alcohol. Every year the American cancer society diagnosis founds new cases related to cancer in which the last year 2017 (1,688,780) cases were found while in the current year 2018 (1,735,350) new cases related to cancer, collected by National Center for Health Statistics.

Nanomedicines have gained huge response and compliments within a short period of time. The word nanoparticle was first given by American Physicist lecturer "Richard Feynman" at meeting in California Institute of Technology. It contains identical and unique physical, chemical and biological properties at small scale as compared to other respective higher scales. Nanoparticles are generally having the range size from 1nm – 100nm and they are classified on the basis of organic, inorganic and carbon.

Overall, various innovative strategies for treating brain cancer were covered in this study, with a focus on the effectiveness of targeted nanomedicine. It is critical because of the low rate of survival and the lack of effective treatments to address BBB-related issues, as well as the need for a variety of innovative medicines. The fundamental idea is to treat brain cancers like glioblastoma and glioma with nanomedicines that target specific sites. As we discussed in the review, nanomedicine

has played a significant role in improving brain cancer therapy by directing targeting therapy or boosting the efficacy of drug delivery for current anticancer medicines. Exploring nanomedicine modification and debate has demonstrated more benefit to the BBB idea as well as overall therapies effect against cancer through this review.

Keywords: Cancer, Nanomedicine, Brain tumor, Neurofibromatosis

1. Introduction:

The term "cancer" refers to a group of illnesses that are characterized by aberrant cell growth that has the capacity to invade or spread to different parts of the body. it began to divide quickly and without a pause. According to the World Health Organization, cancer is the second biggest cause of death worldwide, accounting for an estimated 9.6 million deaths in 2018, with most cancers accounting for around one in every six fatalities. More than 70 percent of all cancer deaths globally take place in low- and middle-income countries. The five most prevalent dietary and behavioral risks—a high body mass index, a lack of fruits and vegetables, a lack of physical activity, tobacco use, and alcohol use—account for around one-third of cancer fatalities. Every year the American cancer society diagnosis founds new cases related to cancer in which the last year 2017 (1,688,780) cases were found while in the current year 2018 (1,735,350) new cases related to cancer, collected by National Center for Health Statistics.

Cancer of the brain is the reasons for heavy impact nowadays in the lives of children, women, and men which placing a significant number of load on the healthcare system. In 2018 greater than 1935 new instances related to brain cancer was recognized in Australians. The majority of cancer cells (malignant cells) develop inside the brain tissue, making brain cancer a disease of the brain. Cancer cells grow into a mass of cancerous tissue (tumour) that obstructs brain functions such as muscle control, sensation, memory, and other normal bodily activities. Tumors made up of cancer cells are known as malignant tumours, whereas those made up of noncancerous cells are known as benign tumours. Primary brain tumours are cancer cells that originate in brain tissue, whereas metastatic or secondary brain tumours are cancer cells that travel from other parts of the body to the brain. According to statistics, most brain malignancies occur seldom, hence it should not be considered a common ailment. According to the National Cancer Institute (NCI) and the American Cancer Society, cancer can affect 23,770 new people per year, resulting in 16,050 fatalities. Hereditary genetic diseases such as neurofibromatosis, tuberous sclerosis, and a few others account for only

approximately 5% of brain tumours.

2. Etiology of Brain Cancer:

A brain tumor is mass of a cell which is not a normal cellular part of the brain. The brain tumor can be classified in two types as followings below:

- **Primary brain tumors:** They generally occur inside the brain tissue and have a tendency to stay there most effective.
- **Secondary brain tumors:** They are mostly not unusual cancer which starts primitively elsewhere inside the body and move to the brain and various aspects of the human body The most frequent type of brain tumour is secondary brain cancer, which is more common than primary brain cancer.

Furthermore**,** Brain tumors are normally no longer alike apart from the fact that their origin is from a comparable kind of brain tissue. They particularly depend upon the how cells in the tumor seem microscopically, those grades make us aware of enhance growth and according to National Cancer Institute The National Cancer Institute (NCI) classifies tumours into the following categories, ranging from benign to aggressive.

GRADE 1: The tissue is non-cancerous, has the appearance of normal cells, and grows slowly.

GRADE 2: The tissue is cancerous and seems to have fewer normal cells than grade 1.

GRADE 3 The tissue is cancerous, has an aberrant appearance, and is actively expanding.

GRADE 4 The tissue is cancerous, has an odd appearance, and grows rapidly.

2.1 Types of brain tumor

The tumors are categorized with the aid of the type of cellular wherein it becomes first advanced. According to some document of 2016 National Brain Tumor Society determined over 120 specific types of brain tumors and the most common types of brain cancer are:

i. Gliomas

Until date, malignant gliomas have been the most common and deadly brain malignancies. They develop inside the glial cells of the central nervous system (CNS). Researchers believe that this type of brain cancer may also be resistant to treatment because it contains stem cells that are responsible for the formation of blood vessels (angiogenesis), the spread of the tumour within the brain (metastasis), and resistance to all types of treatments. Gliomas are mainly divided into 3 parts i.e.:

Table-1: Types of Gliomas

Astrocytomas	Found in cerebrum and cerebellum, about 50% brain tumor arises from this part and most aggressive tumor consisting poor prognosis Glioblastoma subtype of Astrocytomas (Abbott et al., 2006).
Oligodendrogliomas	Found in cerebral hemispheres, about 4% of primary tumor make up, approx 55% of Oligodendrogliomas occur in people at age b/w 40-64 and produce myelin which is found in the brain to increase impulse speed (Zlokovic, 2008).
Ependymomas	Found in ependymal cells where cerebrospinal fluid(CSF) is formed and stored, about 8 -10% of children suffer from the brain tumor and they are also found in the spinal cord and ventricle lining (Wolburg and Lippoldt, 2002).

ii. Non-gliomas

This type of tumor does Glial cells do not produce and some of its examples contain meningiomas and medulloblastomas.

Table-2: Types of Non-gliomas

Meningiomas	They are benign in nature which develops in meninges, a membrane covering in Arachnoid cells typically develop in the brain and spinal cord. These cells are responsible for 13% to 30% of all tumours that occur, as well as some very rare tumours. Every year, around 2 out of every million people are affected. The risk rises with age, and it is mostly observed in women.
Medulloblastomas	This tumour is more typically discovered in youngsters and is found in the posterior fossa — a specific location inside the cerebral cavity that contains the brain stem and cerebellum.



Figure 1: Types of brain tumor

2.1.1. Risk Factor of Brain Cancer

For most kinds of cancer, unique hazard elements have now not been diagnosed. Some threat (and potential hazard) variables have, nevertheless, been identified. They are as follows:

a) Age: Most malignancies become more dangerous as you become older. Neuroblastoma, on the other hand, is an exception; it usually affects children in their early years.

b) Heredity: Some genetic diseases have been identified as potential risk factors for developing brain cancer. They are as follows:



Figure 2: Genetic Diseases identified as potential risk factor.

- **Neurofibromatosis type1:** A Changes in skin pigmentation and an increase in tiny tumours on the skin, brain, and other regions of the body describe this condition. People with this condition are more likely to develop shwannomas, meningiomas, neurofibromas, and various forms of gliomas. Cancerous tumours form along the nerves in adults with this condition.
- **Type 2 neurofibromatosis:** This is a rarer occurrence than in the instance of neurofibromatosis type 1, mutations in the NF2 gene are linked to the disease. The NF2 gene mutation is inherited from both the mother and father in around half of all cases of neurofibromatosis type 2. Acoustic neuromas, meningiomas, and spinal wire ependymomas are all linked to this condition. The signs and symptoms of the symptoms and signs and symptoms of the symptoms and signs and symptoms of This condition usually manifests itself during a person's formative years or in their early twenties (18-24 years antique). Balance issues and hearing loss are examples of symptoms
- **Tuberous sclerosis** is a hereditary genetic illness that causes tumours to form in the skin, brain/nervous system, kidneys, and coronary heart. The This ailment's tumours have a proclivity for being non-cancerous (benign), but they can also be malignant. Tuberous sclerosis is caused by random mutations in the TSC1 and TSC2 genes in the majority of cases. Apart from having a family member who has the condition, there are no known risk factors for this illness. However, in the vast majority of instances, no family history of tuberous sclerosis can be found.
- **Von Hippel-Lindau syndrome (VHL):** This disorder is linked to the development of benign and malignant tumours in specific regions of the body. This syndrome is caused by the VHL gene, which is a tumour suppressor gene. VHL gene mutations result in VHL proteins that are unable to properly regulate cell survival and proliferation.
- **Li-Fraumeni syndrome:** This rare disorder is linked to an increased risk of developing gliomas and other malignancies. The CHEK2 gene and the TP53 gene have been associated to Li- Fraumeni syndrome in studies. TP53 gene mutations are inherited in about half of Li-Fraumeni syndrome families.

c) Viruses, such as retroviruses, papovaviruses, and adenoviruses, have been shown to cause brain tumours in animals, although few human studies have found a relationship between viral infections and brain tumours. Viruses, on the other hand, have not been eliminated as a potential hazard factor, and research in this area is still underway.

d) Head injury and trauma: Researchers are actively investigating the possibility of relationship between head injuries and meningiomas. Many children diagnosed with brain tumours suffered head injuries/trauma at some point in their lives, according to studies.

e) Vitamins: Research suggests a possible link between N-nitroso compounds consumed during pregnancy and a higher risk of brain tumour development in offspring.

2.2 Brain permeability factor (BBB):

As radiotherapy has shown greater improvement in treatment of malignant glioma, chemotherapy is also beneficial as per database, within research trials it shows whether or not, and to which stage chemotherapy has shown better survival benefit to patients The presence of the blood brain barrier (BBB) makes it difficult to transport high concentrations of drugs to the brain Endothelial cells in brain capillaries form a network that ensures a tight transfer law between the circulation and brain tissue. Many treatment procedures were allowed to cross the BBB, each with its own set of benefits and risks. Glioblastoma (GB) tumours, like cancers of other systems, are supplied by a 'leaky' vasculature and a chaotic network of blood vessels created by a high rate of angiogenesis, which marks high-grade malignant tumours The observation that molecules and tiny particles can more easily extravasate from tumour vasculature and are inefficiently reabsorbed The enhanced permeation and retention (EPR) effect became the most common finding in cancer therapy research as a result of inadequate lymphatic drainage They've become more interested in cancer medication delivery because of the capacity to take use of the EPR effect, as well as the occurrence of pharmaceuticals within cells and boosting nanoparticle half-life. Particles having a diameter of less than 100 nm extravasate preferentially from tumour vasculature due to increased vascular permeability relative to normal tissue, whereas particles larger than 20 nm are retained in tumour tissue rather than returning freely to the circulation. This effect is generally determined by the physical site of nanoparticles, primarily their size and ability to stay in circulation long enough to eliminate tumours, but it is severely limited by a loss of specificity for specific tissues. But the main question is whether or not BBB is a major cause of inefficient drug delivery to brain cancer, which has not been seen in many previous years, even in literature searches, but many studies using chemotherapeutics have found a significant increase in drug retention at glioma sites compared to other tissues Various ways for increasing the penetration of the BTBB must also be investigated. One method to improve delivery is to employ BBB disruption to disrupt growth in a similar way.

Increase the local osmotic strain inside the brain vasculature by utilising hyper osmotic agents to increase the permeability of these vessels. However, this technique is regarded to have more variability from patient to patient, making it difficult to utilise consistently Furthermore, those total BBB disruption approaches cause a reduction in the integrity of the entire BBB, not just the tumor's vasculature, which may have an unfavorable effect on healthy brain tissue. Apart from non-unique distribution of the chemotherapeutic to healthy tissue, which could result in undesirable toxicity and dose-restricting side effects, BBB rupture can also allow unwanted chemicals from the bloodstream to infiltrate into the brain via the globally impaired BBB To avoid completely destroying the BBB, a variety of strategies were used to breach the BBB via the nanoparticle drug carriers themselves.

3. Nanomedicines

Nanomedicines have gained huge response and compliments within a short period of time. The word nanoparticle was first given by American Physicist lecturer "Richard Feynman" at meeting in California Institute of Technology. It contains identical and unique physical, chemical and biological properties at small scale as compared to other respective higher scales. Nanoparticles are generally having the range size from 1nm – 100nm and they are classified on the basis of organic, inorganic and carbon. While organic nanoparticle commonly has SLN, NLC, Dendrimers, Liposomes, and Ferritin etc. These are biodegradable, non-toxic but are sensitive to light, heat and electromagnetic radiation. They have identical characteristic for loading drugs, to provide stability and effective targeted drug delivery. Inorganic NP is generally made by metals bases such as Al, Cd, Cu, Au, Fe, Pb, Ag, and Zn are some of the most common metals. Another one is carbon base NP which completely made of carbon such as Fullerton's, Carbon nanofibers and Carbon black. There are various types of lipids, surfactant and co-surfactants are used for preparations of nanomedicine.

3.1 Importance of Nanoparticle in breast cancer therapy

Nanoparticles have shown greater potential at large scale for use of nanotherapy in various types of cancer disease. Numerous types of drugs had been launched in the market for treatment of cancer and many innovative method and drugs are used for the reduction of this disease. The nanoparticle has offered it a new form of invasive measure for treatment of Brain Cancer by overcoming the problems related to BBB (blood-brain barrier). Nanoparticles have greater potential, various characteristic and include that it can easily be adapted to fulfill roles within greater advantages. As we know that NP size lies from 1nm- 100nm but in few studies, it is

found that smaller particle size of NP increases various advantages related to its physiological barrier, its specific target tissue, their biodistribution, half-life and possibility to target particular tissue. Using nanoparticle for treatment of cancer is one of the most beneficial methods that enhance drug delivery, specific targeting towards tissue and enhances the sensitivity of cell towards radiation. NP is used as a medium to achieve modification in ‘targeting' for exposed of surface area, usually, the nanoparticle is coated with particular proteins or antibiotic which is highly compatible towards desired targeted tissues. The main benefit of using targeted nanoparticle is it minimizing target advance effect and also lessen the dosage form. As during the administration of ‘free drugs' it may get distributed to various parts of the body and increase side-effect also due to a non-specific targeting of tissue, hence limiting the action of NP along with their therapeutic action and only targeted toward particular tissue will reduce adverse effects. The advance process to targeted delivery of NP ability for the slow release of therapeutic dose and through this process it explains why nanoparticle has greater enhanced delivery and maximum potential to achieve desired therapeutic range. Another advancement of using NP therapy is that we can use multiple combinations of the dosage form in process of achieving optimal against cancer. However, being so much advanced technique and potential benefit It's crucial to note that this technology is still relatively new, and that such large doses of medication can cause toxicity, therefore we can only use it after comprehensive research.

3.2. Brain cancer and its recent advances treatment

As above mention Brain cancer is a disorder in which cancerous cells develop in the brain. inside the brain and create tumor result to form various types of brain cancer and grades which are severely affecting brain functions. But the current topic is focusing on Gliomas and 4-Glioblastomas for this disease, well it is a type of brain cancer that more especially occur in Astrocytoma, as glioblastoma is the most effective form of BC. The most common treatment is surgery, chemotherapy and radiation therapy and it is followed by the combination therapy . There are various types of drugs used in the treatment of BC but most are TMZ, it is most noninvasive and has the most effective therapeutic range. Apart from this Revacizumab is an anti-angiogenesis therapy used for the treatment of Glioblastoma Most medications are unable to pass through the BBB (Blood Brain Barrier), however TMZ can easily pass through. While receiving all of the combo therapy, the brain nevertheless experiences some medical issues as a result of the treatment's adverse effects. During early stage therapy this treatment will show

positive results but after prolong process some limiting effect will be seen during the course of the disease and major cause of these side-effects is due to present of malignancies in the brain which generally causes the medical problem so advances therapy i.e. nanotherapy is the current treatment for brain targeting.This study further advises that it inhibit the enhancement effect of radiation, lowering dosage form and reduction of side effects that occur during treating this disease. This article will highlight the promising benefits of targeting therapies that could be effective in the fight against brain cancer using sophisticated nanoparticle medicines.

The use of nanomedicine in the treatment of brain cancer is becoming more common. Nanomedicine has offered up new possibilities for treating and diagnosing brain cancer. Because the material used in the process is biocompatible, and the range of nanocarrier design techniques and composition of this nanomedicine is a wider range, they are very beneficial in the treatment of various forms of cancer. They also offer a significant benefit in the treatment of brain tumours since they bypass the BBB (blood-brain barrier) and allow for precise targeting. Nanoparticles have been discussed as a possible positive effect, and some are now being investigated. An adult's brain vasculature surface area is estimated to be between 12m2 and 18m2. The use of nanoparticles in the treatment of brain cancer for better therapeutic delivery is in the works, and some of the nanoparticles with the greatest potential in the treatment of brain cancer are listed below.

3.2.1. Glutathione-targeted PEGylated Liposomes

Table-3: Strategies for nanomedicine in delivery to the brain

Strategies to overcome BBB(blood brain barrier)	**Examples**
a) Enhanced permeation and retention effect	Size smaller (<100 or <20nm) inorganic nanoparticle incorporated within the tumor site.
b) BBB- penetration of nanoparticles	Cationized serum albumin is used to coat the surface. Conjugation with peptides and toxins generated from BBB- penetrating viruses. Coating with LDL receptor ligands such as apoA-1 and apoE. Coating with apolipoprotein-increasing surfactants like Poloxamer 188. Conjugation with BBB endothelial cell-binding ligands, such

For the sake of safety and to improve drug delivery in the brain by overcoming the BBB

	as insulin and transferring receptors.
a) Increase the time spent in circulation	PEG molecules are used to cover the surface.
b) Anti-degradation protection for treatments	Nucleic acid condensation with metallic nanoparticles.
a) Increase the dispersion of nanoparticles	Reduce the size of the nanoparticles to 70nm. A dense layer of PEG was used to modify the surface.
b) Increase bulk flow due to convection of nanoparticles	The transport of poly (lactic-co-glycolic acid), lipid-based, dendrimer, and virus nanoparticles is improved by convection.

obstacle. The use of glutathione PEGylated liposomes as a targeted approach has recently gained a lot of attention. When polyethylene glycol (PEG) is covalently connected to phospholipids, GSH-PEGNLs were both incorporated into glutathione, with tripeptide as this lipid is a natural macromolecular in the body is able to successfully survive systemic circulation and long lasting inside the body. The US Food and Drug Administration has approved the use of this combination because PEGylation of the outer membrane of GSH-PEG NL increases the probability of avoiding drug degradation and improves the effectiveness of brain administration .The addition of PEGylation increases nanoparticle stability and prolongs circulation time and incorporating glutathione will specifically help to target the brain, as glutathione is a prominent antioxidant, and the brain requires the highest amount of antioxidant, and it is widely expressed on the BBB and brain tissue. According to Rip et al. in a 2014 study, higher doses of GSH-PEG NL's in the form of liposomes produce better results in the brain, so it's mostly thought that the glutathione receptor is responsible for the significant therapeutic effect of GSH-PEG NL, which was demonstrated in a 2015 study by Lee et al. by taking the next step in targeted delivery using in- vivo studies in neurological disease, particularly multiple sclerosis. The medication Methylprednisolone (MP) was used in this investigation. encapsulated and applied to the treatment of multiple sclerosis When MP medication was encapsulated in 2B3-201, Lee.et.al reported an increase in therapeutic use. The mice were given the highest and minimum doses of PEG NL all MP, and the results demonstrate that free MP produces unsatisfactory outcomes, whereas PEG NL all MP requires ten times the dosage to provide the same advantage. As a result of the favourable results of the 2B3-201 encapsulated MP delivery channel, this study does not provide a direct result for brain cancer, but it does provide some positive elements of GSH-NLs for brain cancer treatment .During the same year as Lee.et.al, Gaillard. et.al discovered the usefulness of GSH-NLs in the treatment of brain

cancer. In an in vivo murine model of malignancy Because doxorubicin (DOX) is extensively used as an anti-cancer treatment, DOX containing GSH-PE NLs were created encapsulated with 2B3-101 for non-targeted PEG-NLs as well as freely administered DOX for this investigation. The major goal of Gaillard.et.al was to see if GSH-PEG NLs might boost DOX treatment occurrences against brain tumours and if they were efficacious as free and non-targeted counterparts. The results show that GSH-PEG NLs encapsulated DOX in 2B3-101 has a greater benefit in reducing tumour growth, and another important finding was that animals given 2B3-101 had a 3 fold increase in DOX concentration in the brain, compared to a 1.5 fold increase in free DOX concentration in non-treated animals. As a result of the targeted PEG NLs encapsulating DOX, this study concludes that a two-week continuous dose of 2B3-101 provided a larger benefit, with a median survival time increase of
38.5 percent, which adds to their tumour regression conclusion. It was also discovered that using GSH-PEG NLs increased medication delivery, specifically DOX, to brain tumour cells

3.2.2. Gold Nanoparticles:

They've gotten a lot of attention in the form of nanomedicine for cancer treatment in the last several years because of their better potential to incorporate into malignant tissue, as well as the alteration (Sanna et al., 2014). As a nanodevice for selective targeting and administration of a medicine in the precise tumour site, nanotechnology is the most recent treatment. AgNa possesses unique features that can be used in a variety of drug delivery applications. High surface area to volume ratio, surface plasmon, surface chemical, multifunctional, and stable formation are some of these features. They are generally non-toxic, have a high permeability, and have the extra virtue of being quickly pierced and allowing drug integration at the tumour site. Despite all of these advantages, there is one crucial issue to consider before employing gold nanoparticles in clinical applications: biocompatibility .The cytotoxicity of nanoparticles, which is dependent on their size, shape, surface qualities, and chemical production, must be studied appropriately, as we know they are inert, making them generally biocompatible .Nonetheless, the The major question of AuNP toxicity appears to be under constant scrutiny, with different studies yielding diverse results . While AuNPs smaller than 5 nm behave similarly to 'bulk' gold and are typically considered innocuous, a number of parameters, including size, coating, related stabilisers, and electrical charges, have been linked to AuNP toxicity. While the majority of in vitro studies support the notion that AuNPs are harmless, the results of in vivo investigations are inconsistent. Even though these identical nanoparticles were previously mentioned as being harmless through in vitro investigative study, a study by

Chen et al. in 2009 claims that AuNPs of varied sizes were fatal within mouse models. Overall, it appears that AuNPs cause minor toxicity, but due to the lack of in vivo studies, there is a strong likelihood that toxicity will continue to be a factor as this nanoparticle progresses in its fight against brain tumours .Despite the negative results on AuNP treatment for brain tumours, Dhar et al. published a study in 2010 that showed the development of sophorolipid-coated Gellan Gum reduced AuNPs (SL-GG- AuNPs) in human glioma cells and glioma stem cell lines However, while other studies have discovered that AuNP has qualities, this work demonstrates that determining AuNP effects directly on glioblastoma cells, LN-229 cells, and their related stem cells, HNGC-2 stem cells, is possible. This research on stem cells is particularly relevant because, in general, they multiply more slowly than adult tumour cells (Chen et al., 2009), making them harder to target with effective anticancer medicines, allowing for cancer treatment The results of this study demonstrate that SL-GG-AuNPs were injected into malignant cells for 3 hours, resulting in AuNPs forming in the cytoplasm and perinuclear regions of the cell. The researchers discovered that when they were given AuNPs at the greatest dose (12.5 mg/l), 80 percent of the bacteria died. However, the cells become viable after 48 hours. While sophorolipids were linked to a 50% drop in viability, the Gellan Gum was not, indicating that adding individual sophorolipids increased cytotoxicity. The experiment was then repeated using AuNPs combined with DOX, an anticancer medication. Only 27% of LN-229 cells remain competent after 24 hours when SL- GG-AuNPs are coated with DOX molecules. containing hydrogen bond formation and Gellan Gum's sugar components are combined with freshly produced DOX-SL-GG-AuNPs, resulting in more cytotoxic potential than non-DOX coated counterparts. As it was discovered that free DOX medication can only allow 59 percent of cells to live after 48 hours, the cells' ability to survive was reduced again. While the capacity of HNGC-2 glioma stem cells was reduced, it was not to the extent of mature and develop cells, with 32 percent ability to DOX and 9 percent ability to DOX-SL-GG-AuNP therapy. As a result of this research, it is obvious that cytotoxicity is favourable for modified AuNPs and that they have a stronger ability to act against glioma cells and stem cells. Various studies imply that AuNPs can be applied in vitro models. For example, a 2017 study by Raliya et al. looked into the larger potential for AuNPs to be transported to the brain via the olfactory neuronal route, employing an invertebrate model.

3.2.3. Nanoparticle – albumin-bound drugs

Human serum albumin [HSA]-NPs (nanoparticle-containing albumin) could be employed to actively transport target therapies into tumour cells. As we know, albumin is abundant in human blood. As a result, HAS-NP therapy is prone to bloodstream degradation, which can be mitigated by improving the chance of drug shipping success. This type of route offers a fantastic healing potential with high effectiveness because tumour cells contain an excessive amount of vitamins and metabolites, which are needed for malignancy microvasculature and treatment enhancement. As a result, albumin is capable of transporting metabolites to specific types of tissue or in the treatment of most tumours (Lomis et al., 2016). They can also bypass gaps in endothelial cells and transport directly to inner tissue via the albumin gp60 pathway, which is more effective than

the BBB. Because this method of transport is more novel and has the potential to produce precise HAS-NPs for the treatment of brain cancers, Dreis et al. published a research in 2007 that formulated nanoparticles via the HAS-NP therapeutic technique. In this research, numerous types of approaches were used according to for testing on neuroblastoma brain cancers mobile line research on UKF-NB-three and IMR 32. These nanoparticles were loaded with DOX, which was integrated into the matrix of HAS-NPs, and they were cultured with neuroblastoma for five days, resulting in decreased tumour cell visibility concentration of nanoparticles become low. In this study, it was discovered that several HAS-NPs elements are influenced by ph, nanoparticle loading, and a higher awareness of DOX, all of which aid in the reduction of tumour cell appearance. As a result, this observation suggests that loading DOX on HAS-NPs has a stronger anticancer effect than free DOX in 2010, organised aim nanoparticle HAS-NPs with folic acid for a most cancers cellular, and this changed becoming evaluated on human neuroblastoma cell line UKF-NB-3 and rat glioblastoma cell line 101/8, wherein increased nanoparticle uptake was discovered in 2016, published a major study on the conjugation of lapatinib-loaded HAS-NPs, which are utilised to treat breast cancer and also treat brain cancer. Using this technique, HAS- NPs in vitro and in vivo data reveal better LHNP anti-metastasis efficacy and increased stability in toxic human plasma in both conditions. For brain cancer, it is critical for LHNPs to adhere to malignant cells, and the effect on 4T1 cancerous cells shows a 45.6 percent reduction after 90 minutes when compared to untreated 4T1 cells (Wan et al., 2016). With this current information gap, further research into the nanoparticles' brain cancer packaging provides room for this. Wan et al. published a major study in 2016 on the conjugation of lapatinib-loaded HAS-NPs that are utilised for treating

brtreatment alternative to development, arranging essential facts such as biodistribution and toxicity. This revelation has significantly increased the importance of survival and elevated the role of survival as a brand-new treatment objective for brain malignancies.

3.2.4. Nanomedicine movement within the brain tissue

Once a medication has passed through the BBTB and into the brain tissue, it faces further challenges. Because surgical excision is frequently the first step in treatment, local delivery of a chemotherapeutic to the tumor's specific site is possible and can be a cost-effective technique to bypass the BBB's delivery bottleneck.

3.2.5. Nanoparticle diffusion in the tissue:

To overcome the inadequate mobility of medicines within the brain interstitium, several ways were used. Attempts to better understand the size of the extracellular space, which is modelled as pores through which trash might infiltrate inside the brain, revealed that particles must be 30–70 nm in diameter or smaller to pass through the interstitium of the brain PLA–PEG nanoparticles were loaded with aclarubicin and coated with cationic albumin in one investigation with particles with a hydrodynamic diameter of at least 114 nm. br The authors demonstrated improved survival in a rat glioma model using these nanoparticle components by preserving particles in the approximate variety stated above, implying that the system became capable of effectively supplying debris through the disrupted BBB and passing through the tumour interstitium. However, it has become obvious that while particle size is important, nanoparticle surface residences can also influence transport through the brain. When polystyrene nanoparticles (>100 nm) and quantum dots (35 nm) were left unmodified or lined in moderation with PEG, Nance et al. discovered that they diffused very slowly across the brain interstitium; however, a dense coating of PEG allowed for significantly increased diffusion via Seve. the Particles in the brain with a hydrodynamic diameter of at least 114 nm. As a result, while smaller particles tend to allow more diffusion than bigger ones, the maximum limit of nanoparticle size can be extended by surface alterations that increase particle diffusivity, boosting the particle's capabilities as drug-loaded nanodevices.

Future Prospective While there has been substantial progress in brain cancer research and scientific exercise in recent years, it has been slow and incremental. Nanoparticles are being used in this field. has been aided by a lack of current solutions to many of the barriers that obstruct similar growth. Clinical translation of these technologies, in particular, has been slow;

just a few related studies have progressed to clinical trials, and even fewer for brain applications Many researchers have noted the difficulties in translating nanomedicine and its usage in cancer therapy demonstrate more success in the treatment of brain cancers, including glioma and glioblastoma multiforme, as well as the use of each nanoparticle and surviving therapy. As far as I know, Because of their small size and highly variable physical, chemical, and biological features, nanoparticles are intrinsically well-suited for cancer treatment. Because numerous aspects for drug delivery and imaging can be incorporated at the same time, nanomedicine has a great therapeutic price potential. The cutting-edge progress in brain cancer treatment with nanoparticles such as GSH- PEG NLs, AuNPs, SPIONs, and nanoparticle–albumin-bound tablets is highlighted in this study. Delivery will be impeded by incomparable techniques, which include off-target tissue buildup, toxicity concerns, and differences between in vitro and in vivo investigations, just as it is with nanoparticle-brought therapies. Overall, according to the studies included in this review article, these methods are being investigated for treatment of such ailments, which should lead to more positive results in the coming years.

Conclusion

Overall, various innovative strategies for treating brain cancer were covered in this study, with a focus on the effectiveness of targeted nanomedicine. It is critical because of the low rate of survival and the lack of effective treatments to address BBB-related issues, as well as the need for a variety of innovative medicines. The fundamental idea is to treat brain cancers like glioblastoma and glioma with nanomedicines that target specific sites. As we discussed in the review, nanomedicine has played a significant role in improving brain cancer therapy by directing targeting therapy or boosting the efficacy of drug delivery for current anticancer medicines. Exploring nanomedicine modification and debate has demonstrated more benefit to the BBB idea as well as overall therapies effect against cancer through this review. In addition, the development of survivin-associated medicines, including as inhibition and immunisation, has progressed, with the potential to be used in the fight against these cancers being examined. Because surviving expression is elevated in a variety of malignancies, treatments that target survivin can be focused primarily on cancers. Treatments aiming targeting survivin have the ability to both directly and indirectly block survivin as well as trigger survivin-directed immune responses, as demonstrated by the multiple initiatives highlighted. Overall, it is obvious that the fields of nanoparticle creation and survivin therapy are growing at a faster and faster rate, resulting in capability advantages for the treatment of brain cancer.

REFERENCES

1) Abbott, N. J., Patabendige, A. A. K., Dolman, D. E. M., Yusof, S. R. and Begley, D. J. (2010). Structure and function of the blood-brain barrier. *Neurobiol. Dis.* 37, 13–25. doi:10.1016/j.nbd.2009.07.030.
2) Abbott, N. J., Rönnbäck, L. and Hansson, E. (2006). Astrocyte-endothelial interactions at the blood-brain barrier. *Nat. Rev. Neurosci.* 7, 41–53. doi:10.1038/nrn1824.
3) Adewale, O. B., Davids, H., Cairncross, L. and Roux, S. (2019). Toxicological Behavior of Gold Nanoparticles on Various Models: Influence of Physicochemical Properties and Other Factors. *Int. J. Toxicol.* 38, 357–384. doi:10.1177/1091581819863130.
4) Agarwal, S., Manchanda, P., Vogelbaum, M. A., Ohlfest, J. R. and Elmquist, W. F. (2013). Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: Findings in an orthotopic rat xenograft model of glioma. *Drug Metab. Dispos.* 41, 33–39. doi:10.1124/dmd.112.048322.
5) Alkilany, A.M. and Murphy, C.J. (2020). Toxicity and Cellular Uptake of Gold Nanoparticles: What We Have Learned So Far *. *Nanomater. Neoplasms*, 657–698. doi:10.1201/9780429027819-11.
6) Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmel and, A. B., et al. (2006). Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. *Nature* 444, 756–760. doi:10.1038/nature05236.
7) Barua, S. and Mitragotri, S. (2014). Challenges associated with penetration of nanoparticles across cell and tissue barriers: A review of current status and future prospects. *Nano Today* 9, 223–243. doi:10.1016/j.nantod.2014.04.008.
8) Chen, Y. S., Hung, Y. C., Liau, I. and Huang, G. S. (2009). Assessment of the in vivo toxicity of gold nanoparticles. *Nanoscale Res. Lett.* 4, 858–864. doi:10.1007/s11671-009-9334-6.
9) Daraee, H., Etemadi, A., Kouhi, M., Alimirzalu, S. and Akbarzadeh, A. (2016). Application of liposomes in medicine and drug delivery. *Artif. Cells, Nanomedicine Biotechnol.* 44, 381–391. doi:10.3109/21691401.2014.953633.
10) De Jong, W. H. and Borm, P. J. A. (2008). Drug delivery and nanoparticles: Applications and hazards. *Int. J. Nanomedicine* 3, 133–149. doi:10.2147/ijn.s596.
11) Deeken, J. F. and Löscher, W. (2007). The blood-brain barrier and cancer: Transporters,

treatment, and trojan horses. *Clin. Cancer Res.* 13, 1663–1674. doi:10.1158/1078-0432.CCR-06-2854.

12) Dhar, S., Reddy, E. M., Prabhune, A., Pokharkar, V., Shiras, A. and Prasad, B. L. V. (2011). Cytotoxicity of sophorolipid-gellan gum-gold nanoparticle conjugates and their doxorubicin loaded derivatives towards human glioma and human glioma stem cell lines. *Nanoscale* 3, 575–580. doi:10.1039/c0nr00598c.

13) Dósa, E., Guillaume, D. J., Haluska, M., Lacy, C. A., Hamilton, B. E. and Njus, J. M., et al. (2011). Magnetic resonance imaging of intracranial tumors: Intra-patient comparison of gadoteridol and ferumoxytol. *Neuro. Oncol.* 13, 251–260. doi:10.1093/neuonc/noq172.

14) Dreis, S., Rothweiler, F., Michaelis, M., Cinatl, J., Kreuter, J. and Langer, K. (2007). Preparation, characterisation and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles. *Int. J. Pharm.* 341, 207–214. doi:10.1016/j.ijpharm.2007.03.036.

15) FB;, F., T;, F., RM;, B., A;, M., JM;, S., A;, S., et al. (2007). Malignant astrocytic glioma: genetics, biology and paths to treatment. *Genes Dev.*, 2683–2710.

16) Fenstermaker, R. A. and Ciesielski, M. J. (2014). Challenges in the development of a survivin vaccine (SurVaxM) for malignant glioma. *Expert Rev. Vaccines* 13, 377–385. doi:10.1586/14760584.2014.881255.

17) Gahramanov, S., Muldoon, L. L., Varallyay, C. G., Li, X., Kraemer, D. F., Fu, R., et al. (2013). Pseudoprogression of glioblastoma after chemo- and radiation therapy: Diagnosis by using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging with ferumoxytol versus gadoteridol and correlation with survival. *Radiology* 266, 842–852. doi:10.1148/radiol.12111472.

18) Gaillard, P. J., Appeldoorn, C. C. M., Dorland, R., Van Kregten, J., Manca, F., Vugts, D. J., et al. (2014). Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101). *PLoS One* 9. doi:10.1371/journal.pone.0082331.

19) Gao, H., Yang, Z., Cao, S., Xi, Z., Zhang, S., Pang, Z., et al. (2012). Behavior and anti-glioma effect of lapatinib-incorporated lipoprotein-like nanoparticles. *Nanotechnology* 23. doi:10.1088/0957-4484/23/43/435101.

20) Geldenhuys, W., Wehrung, D., Groshev, A., Hirani, A. and Sutariya, V. (2015). Brain-targeted delivery of doxorubicin using glutathione-coated nanoparticles for brain cancers.

Pharm. Dev. Technol. 20, 497–506. doi:10.3109/10837450.2014.892130.

21) Guyon, J., Chapouly, C., Andrique, L., Bikfalvi, A. and Daubon, T. (2021). The Normal and Brain Tumor Vasculature: Morphological and Functional Characteristics and Therapeutic Targeting. *Front. Physiol.* 12. doi:10.3389/fphys.2021.622615.

22) Hagenbuch, B., Gao, B. and Meier, P. J. (2002). Transport of Xenobiotics Across the Blood-Brain Barrier. *Physiology* 17, 231–234. doi:10.1152/nips.01402.2002.

23) Huang, S. H., and Juang, R. S. (2011). Biochemical and biomedical applications of multifunctional magnetic nanoparticles: A review. *J. Nanoparticle Res.* 13, 4411–4430. doi:10.1007/s11051-011-0551-4.

24) Hynynen, K., McDannold, N., Vykhodtseva, N. and Jolesz, F. A. (2001). Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits. *Radiology* 220, 640–646. doi:10.1148/radiol.2202001804.

25) Hynynen, K., McDannold, N., Vykhodtseva, N. and Jolesz, F. A. (2003). Non-invasive opening of BBB by focused ultrasound. *Acta Neurochir. Suppl.*, 555–558. doi:10.1007/978-3-7091-0651-8_113.

26) Kaupp, U. B. (2010). Olfactory signalling in vertebrates and insects: Differences and commonalities. *Nat. Rev. Neurosci.* 11, 188–200. doi:10.1038/nrn2789.

27) Khlebtsov, N. and Dykmana, L. (2011). Biodistribution and toxicity of engineered gold nanoparticles: A review of in vitro and in vivo studies. *Chem. Soc. Rev.* 40, 1647–1671. doi:10.1039/c0cs00018c.

28) Laquintana, V., Trapani, A., Denora, N., Wang, F., Gallo, J. M. and Trapani, G. (2009). New strategies to deliver anticancer drugs to brain tumors. *Expert Opin. Drug Deliv.* 6, 1017–1032. doi:10.1517/17425240903167942.

29) Laurent, S., Dutz, S., Häfeli, U. O. and Mahmoudi, M. (2011). Magnetic fluid hyperthermia: Focus on superparamagnetic iron oxide nanoparticles. *Adv. Colloid Interface Sci.* 166, 8–23. doi:10.1016/j.cis.2011.04.003.

30) Ling, Y., Wei, K., Zou, F. and Zhong, S. (2012). Temozolomide loaded PLGA-based superparamagnetic nanoparticles for magnetic resonance imaging and treatment of malignant glioma. *Int. J. Pharm.* 430, 266–275. doi:10.1016/j.ijpharm.2012.03.047.

31) Lomis, N., Westfall, S., Farahdel, L., Malhotra, M., Shum-Tim, D. and Prakash, S. (2016). Human serum albumin nanoparticles for use in cancer drug delivery: Process optimization and in vitro characterization. *Nanomaterials* 6. doi:10.3390/nano6060116.

32) Mazur, J., Roy, K. and Kanwar, J. R. (2018). Recent advances in nanomedicine and survivin targeting in brain cancers. *Nanomedicine* 13, 105–137. doi:10.2217/nnm-2017-0286.

33) Michael F. L.; De Volder, Sameh H.; Tawfick, Ray H.; Baughman and A. John ;Hart (2013). Carbon Nanotubes: Present and Future Commercial Applications. *Science (80-.).* 339,535–539. Available at: http://science.sciencemag.org/content/339/6119/535?sid= 599bece0-48b5-4fcc-9d21- 5e29be89422c.

34) Moghimi, S. M., Hunter, A. C. and Murray, J. C. (2005). Nanomedicine: current status and future prospects. *FASEB J.* 19, 311–330. doi:10.1096/fj.04-2747rev.

35) Munnier, E., Cohen-Jonathan, S., Linassier, C., Douziech-Eyrolles, L., Marchais, H., Soucé, M., et al. (2008). Novel method of doxorubicin-SPION reversible association for magnetic drug targeting. *Int. J. Pharm.* 363, 170–176. doi:10.1016/j.ijpharm.2008.07.006.

36) Neuwelt, E. A., Goldman, D. L., Dahlborg, S. A., Crossen, J., Ramsey, F., Roman-Goldstein, S., et al. (1991). Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: Prolonged survival and preservation of cognitive function. *J. Clin. Oncol.* 9, 1580–1590. doi:10.1200/JCO.1991.9.9.1580.

37) Pachter, J. S., De Vries, H. E. and Fabry, Z. (2003). The blood-brain barrier and its role in immune privilege in the central nervous system. *J. Neuropathol. Exp. Neurol.* 62, 593–604. doi:10.1093/jnen/62.6.593.

38) Pardridge, W. M. (2012). Drug transport across the blood-brain barrier. *J. Cereb. Blood Flow Metab.* 32, 1959–1972. doi:10.1038/jcbfm.2012.126.

39) Park, J. K., Hodges, T., Arko, L., Shen, M., Iacono, D. Dello, McNabb, A., et al. (2010). Scale to predict survival after surgery for recurrent glioblastoma multiforme. *J. Clin. Oncol.* 28, 3838–3843. doi:10.1200/JCO.2010.30.0582.

40) Rae, C. D. and Williams, S. R. (2017). Glutathione in the human brain: Review of its roles and measurement by magnetic resonance spectroscopy. *Anal. Biochem.* 529, 127–143. doi:10.1016/j.ab.2016.12.022.

41) Raliya, R., Saha, D., Chadha, T. S., Raman, B. and Biswas, P. (2017). Non-invasive aerosol delivery and transport of gold nanoparticles to the brain. *Sci. Rep.* 7. doi:10.1038/ srep44718.

42) Rip, J., Chen, L., Hartman, R., Van Den Heuvel, A., Reijerkerk, A., Van Kregten, J., et al.

(2014). Glutathione PEGylated liposomes: Pharmacokinetics and delivery of cargo across the blood-brain barrier in rats. *J. Drug Target.* 22, 460–467. doi:10.3109/1061186 X.2014.888070.

43) Rizvi, S. A. A. and Saleh, A. M. (2018). Applications of nanoparticle systems in drug delivery technology. *Saudi Pharm. J.* 26, 64–70. doi:10.1016/j.jsps.2017.10.012.

44) Rotman, M., Welling, M. M., Bunschoten, A., De Backer, M. E., Rip, J., Nabuurs, R. J. A., et al. (2015). Enhanced glutathione PEGylated liposomal brain delivery of an anti-amyloid single domain antibody fragment in a mouse model for Alzheimer's disease. *J. Control. Release* 203, 40–50. doi:10.1016/j.jconrel.2015.02.012.

45) Sanna, V., Pala, N. and Sechi, M. (2014). Targeted therapy using nanotechnology: Focus on cancer. *Int. J. Nanomedicine* 9, 467–483. doi:10.2147/IJN.S36654.

46) Saraiva, C., Praça, C., Ferreira, R., Santos, T., Ferreira, L. and Bernardino, L. (2016). Nanoparticle-mediated brain drug delivery: Overcoming blood-brain barrier to treat neurodegenerative diseases. *J. Control. Release* 235, 34–47. doi:10.1016/j.jconrel. 2016.05.044.

47) Shao, W., Paul, A., Rodes, L. and Prakash, S. (2015). A New Carbon Nanotube-Based Breast Cancer Drug Delivery System: Preparation and In Vitro Analysis Using Paclitaxel. *Cell Biochem. Biophys.* 71, 1405–1414. doi:10.1007/s12013-014-0363-0.

48) Shevtsov, M. A., Nikolaev, B. P., Ryzhov, V. A., Yakovleva, L. Y., Marchenko, Y. Y., Parr, M. A., et al. (2015). Ionizing radiation improves glioma-specific targeting of superparamagnetic iron oxide nanoparticles conjugated with cmHsp70.1 monoclonal antibodies (SPION-cmHsp70.1). *Nanoscale* 7, 20652–20664. doi:10.1039/c5nr06521f.

49) Siegel, R. L., Miller, K. D. and Jemal, A. (2016). Cancer statistics, 2016. *CA. Cancer J. Clin.* 66, 7–30. doi:10.3322/caac.21332.

50) Sutradhar, K. B. and Amin, M. L. (2014). Nanotechnology in Cancer Drug Delivery and Selective Targeting. *ISRN Nanotechnol.* 2014, 1–12. doi:10.1155/2014/939378.

51) Tavares, M. R., de Menezes, L. R., do Nascimento, D. F., Souza, D. H. S., Reynaud, F., Marques, M. F. V., et al. (2016). Polymeric nanoparticles assembled with microfluidics for drug delivery across the blood-brain barrier. *Eur. Phys. J. Spec. Top.* 225, 779–795. doi:10.1140/epjst/e2015-50266-2.

52) Tzeng, S. Y. and Green, J. J. (2013). Therapeutic nanomedicine for brain cancer. *Ther. Deliv.* 4, 687–704. doi:10.4155/tde.13.38.

53) Ulbrich, K., Michaelis, M., Rothweiler, F., Knobloch, T., Sithisarn, P., Cinatl, J., et al.

(2011). Interaction of folate-conjugated human serum albumin (HSA) nanoparticles with tumour cells. *Int. J. Pharm.* 406, 128–134. doi:10.1016/j.ijpharm.2010.12.023.

54) Wan, X., Zheng, X., Pang, X., Pang, Z., Zhao, J., Zhang, Z., et al. (2016). Lapatinib-loaded human serum albumin nanoparticles for the prevention and treatment of triple-negative breast cancer metastasis to the brain. *Oncotarget* 7, 34038–34051. doi:10.18632/oncotarget.8697.

55) Wolburg, H. and Lippoldt, A. (2002). Tight junctions of the blood-brain barrier: Development, composition and regulation. *Vascul. Pharmacol.* 38, 323–337. doi:10.1016/S1537-1891(02)00200-8.

56) Zhang, T. T., Li, W., Meng, G., Wang, P., and Liao, W. (2016). Strategies for transporting nanoparticles across the blood-brain barrier. *Biomater. Sci.* 4, 219–229. doi:10.1039/c5bm00383k.

57) Zlokovic, B. V. (2008). The Blood-Brain Barrier in Health and Chronic Neurodegenerative